Pinealon: Pineal Bioregulator Research, Melatonin Synthesis & Neuroprotection

Written by NorthPeptide Research Team

For laboratory and research use only. Not for human consumption.

What Is Pinealon?

Pinealon is a synthetic tripeptide with the amino acid sequence Glu-Asp-Arg (glutamic acid–aspartic acid–arginine), commonly abbreviated as EDR. It belongs to the Khavinson family of peptide bioregulators — a class of ultra-short peptides developed at the Saint Petersburg Institute of Bioregulation and Gerontology under the direction of Professor Vladimir Khavinson. These peptides were designed based on the hypothesis that short amino acid sequences derived from organ-specific extracts could regulate gene expression in their tissue of origin.

Pinealon was specifically developed to target the pineal gland, a small endocrine organ located deep within the brain at the epithalamus. The pineal gland’s primary known function is the production of melatonin, the hormone that regulates circadian rhythm and the sleep-wake cycle. Beyond melatonin synthesis, the pineal gland has been studied for its broader roles in neuroendocrine signaling, antioxidant defense, and seasonal biological rhythms.

As a tripeptide — containing only three amino acids — Pinealon is among the smallest biologically active peptides studied in the bioregulation field. This ultra-short structure confers several properties of research interest: resistance to enzymatic degradation compared to larger peptides, the ability to cross biological membranes including the blood-brain barrier, and favorable intracellular uptake. These characteristics have made Pinealon a subject of investigation in neuroendocrine and neuroprotection research, primarily in preclinical models.

Mechanism of Action

Pinealon’s proposed mechanism of action differs fundamentally from that of receptor-binding peptides. Rather than activating a cell surface receptor, Pinealon is classified as a gene regulatory peptide — a compound hypothesized to interact directly with DNA to modulate gene expression in target tissues. This concept, central to the Khavinson bioregulation framework, proposes that specific short peptide sequences can penetrate the cell nucleus and bind to complementary regions of DNA, influencing transcription.

DNA Interaction and Gene Expression

Research conducted at the Saint Petersburg Institute has investigated Pinealon’s interactions with DNA using molecular modeling, electrophoretic mobility shift assays, and gene expression analyses. The proposed mechanism involves the tripeptide entering the cell, translocating to the nucleus, and binding to specific nucleotide sequences within gene promoter regions. This binding is hypothesized to either facilitate or modulate the transcription of genes associated with pineal gland function and neuroprotection.

Specifically, Pinealon has been investigated for its ability to regulate genes involved in:

• Melatonin synthesis — Research has examined Pinealon’s effects on the expression of arylalkylamine N-acetyltransferase (AANAT) and hydroxyindole-O-methyltransferase (HIOMT), the two key enzymes in the melatonin biosynthesis pathway. Preclinical studies have reported upregulation of these enzymes in pinealocyte cultures treated with Pinealon.
• Circadian clock genes — The molecular circadian clock operates through transcription-translation feedback loops involving genes such as CLOCK, BMAL1, PER, and CRY. Pinealon has been studied for its potential influence on the expression of components within this regulatory network.
• Neuroprotective gene pathways — Research has investigated Pinealon’s effects on the expression of genes encoding antioxidant enzymes, anti-apoptotic proteins, and neurotrophic factors in central nervous system cell models.

It is important to note that the gene regulatory peptide hypothesis, while supported by a body of research from the Khavinson group and collaborating laboratories, has not yet achieved the level of independent replication and mechanistic characterization seen with receptor-mediated peptide signaling. The precise molecular details of how a tripeptide interacts with specific DNA sequences remain an active area of investigation, and the field would benefit from additional independent validation studies.

Blood-Brain Barrier Penetration

One of Pinealon’s most frequently cited properties in the research literature is its ability to cross the blood-brain barrier (BBB). The BBB is a highly selective semipermeable membrane that separates circulating blood from the brain’s extracellular fluid, restricting the passage of most molecules — including many peptides — into the central nervous system.

Ultra-short peptides like Pinealon, with molecular weights well under 500 daltons, fall within the size range that research suggests may traverse the BBB more effectively than larger peptide molecules. Studies using radiolabeled and fluorescently tagged short peptides have provided evidence that tripeptides can reach brain tissue following peripheral administration, though the precise transport mechanisms — whether paracellular, transcellular, or carrier-mediated — are not fully elucidated for Pinealon specifically.

This BBB penetration capacity is particularly relevant given that Pinealon’s primary target, the pineal gland, is located within the brain. Without the ability to reach the central nervous system, a peripherally administered peptide would have limited utility for pineal gland-related research applications.

The Khavinson Bioregulator Context

To properly contextualize Pinealon, it is necessary to understand the broader Khavinson bioregulator paradigm. Beginning in the 1970s and continuing through subsequent decades, Vladimir Khavinson and colleagues developed a class of peptide preparations originally extracted from animal organs and later synthesized as short peptide sequences. The foundational concept holds that each tissue type produces characteristic short peptides that regulate gene expression within that tissue, and that administering these peptides exogenously can restore or maintain normal tissue function.

The Khavinson bioregulators include a range of tissue-specific peptides, several of which are available as research compounds:

• Pinealon (EDR) — targets the pineal gland and central nervous system
• Cortagen — targets the brain cortex, studied in models of cognitive function and cortical neuroprotection
• Crystagen — targets the immune system, investigated for immunomodulatory properties in thymus-related research
• Vesugen — targets the vascular system, studied in models of endothelial function and vascular aging
• Cardigen — targets cardiac tissue, investigated in cardiomyocyte culture models

Within this framework, Pinealon occupies a specific niche as the pineal gland bioregulator, with a focus on neuroendocrine regulation, circadian function, and CNS protection. The Khavinson group has published extensively on these peptides in Russian and international journals, with the largest body of clinical data coming from studies conducted in Russia. Researchers outside of Russia have begun independent investigations, though the total volume of non-Russian research on Khavinson bioregulators remains comparatively limited.

It is worth noting that the bioregulator concept — while generating an extensive research portfolio — remains outside the mainstream of Western peptide pharmacology, which tends to focus on receptor-ligand interactions rather than direct peptide-DNA binding. This does not invalidate the research, but it contextualizes why Pinealon and related bioregulators may be less familiar to researchers trained in the receptor-centric paradigm.

Research Applications

Pinealon has been investigated across several research domains, all connected by its proposed relationship to pineal gland function, melatonin regulation, and central nervous system protection. The following areas represent the primary focus of published research to date.

Melatonin Synthesis and Circadian Rhythm

The pineal gland’s production of melatonin follows a well-characterized circadian pattern, with peak synthesis occurring during darkness. This rhythm is essential for synchronizing biological processes with the light-dark cycle. Research has investigated whether Pinealon can influence melatonin output from pinealocytes, the specialized cells of the pineal gland.

In cell culture models using pinealocyte preparations, Pinealon treatment has been associated with increased melatonin secretion and upregulation of melatonin synthesis enzymes. These findings have prompted investigation into whether Pinealon might modulate circadian gene expression more broadly, with preliminary studies examining effects on clock gene mRNA levels in neural tissue cultures.

The circadian research context is particularly relevant given that melatonin production is known to decline with age. The pineal gland undergoes progressive calcification throughout the lifespan, a process associated with reduced melatonin output in aging populations. Pinealon has been investigated in this context as a potential tool for studying age-related changes in pineal function, though direct evidence that Pinealon can counteract pineal calcification has not been established in published research.

Neuroprotection

A substantial portion of Pinealon research has focused on its neuroprotective properties in cellular and animal models of neuronal injury. Studies have examined Pinealon’s effects in several stress paradigms:

• Oxidative stress models — In cortical neuron cultures exposed to hydrogen peroxide or other oxidative agents, Pinealon treatment has been associated with increased cell viability, reduced markers of oxidative damage, and modulation of antioxidant enzyme expression. These findings have been attributed to Pinealon’s proposed ability to upregulate endogenous antioxidant defense pathways.
• Excitotoxicity models — Excessive glutamate signaling is a well-characterized mechanism of neuronal injury. Research has investigated Pinealon’s effects in glutamate-induced excitotoxicity models, with some studies reporting reduced neuronal death in treated cultures.
• Hypoxia models — Oxygen deprivation is a critical factor in ischemic brain injury. Pinealon has been studied in cell models of hypoxic stress, with investigators examining its effects on cell survival, apoptotic markers, and the expression of hypoxia-inducible factors.

The neuroprotective research on Pinealon intersects with broader investigations of melatonin itself, which is a well-established endogenous antioxidant. Whether Pinealon’s neuroprotective effects are mediated primarily through enhanced melatonin production, through direct gene regulatory actions independent of melatonin, or through a combination of both mechanisms, remains an open question in the literature.

Aging and Neurodegenerative Disease Models

The convergence of declining pineal function, reduced melatonin production, and increased oxidative stress with advancing age has positioned Pinealon as a subject of interest in aging and neurodegeneration research. Studies have investigated Pinealon in:

• Aging models — Research in aged animal models has examined whether Pinealon administration can influence markers of brain aging, including oxidative damage accumulation, neuroinflammatory markers, and cognitive performance in behavioral tests. The Khavinson group has published studies reporting improved survival and functional markers in aged rodents treated with Pinealon and related bioregulators.
• Neurodegeneration-related cell models — In vitro studies have examined Pinealon’s effects on neuronal cultures exposed to conditions mimicking aspects of neurodegenerative diseases, including beta-amyloid peptide exposure (relevant to Alzheimer’s disease research) and oxidative stress conditions associated with Parkinson’s disease models.

It should be emphasized that these studies represent preclinical, exploratory research. No clinical trials have evaluated Pinealon for any neurodegenerative condition in human subjects, and the models used in published studies are simplified representations of complex human diseases.

Related Neuropeptide Research

Pinealon’s research profile intersects with several other neuropeptides studied in the context of sleep, circadian function, and CNS protection. Researchers investigating Pinealon may also find relevant context in the literature on:

• DSIP (Delta Sleep-Inducing Peptide) — a nonapeptide studied for its effects on sleep architecture and stress modulation, offering a complementary approach to sleep-related research through receptor-mediated mechanisms rather than gene regulation
• Semax — a synthetic heptapeptide derived from ACTH(4-10), studied for neuroprotective and nootropic properties in models of cerebral ischemia and cognitive function
• Selank — a synthetic peptide based on the immunomodulatory peptide tuftsin, investigated for anxiolytic and neuromodulatory effects in preclinical and clinical studies

Dosing in Published Research

The following table summarizes dosing parameters reported in published Pinealon research. These are presented strictly as a reference for understanding the existing literature and do not constitute dosing recommendations for any purpose.

Research Context	Model System	Dose Range	Route	Duration
Cell culture — neuroprotection	Cortical neuron cultures	0.1–100 nM	Added to culture medium	24–72 hours
Cell culture — melatonin synthesis	Pinealocyte preparations	1–100 nM	Added to culture medium	24–48 hours
Animal models — aging	Aged rats / mice	0.1–1.0 µg/kg	Intraperitoneal / intranasal	10–30 days
Animal models — neuroprotection	Rodent ischemia / stress models	0.1–10 µg/kg	Intraperitoneal	5–14 days
Russian clinical studies (bioregulator formulations)	Human subjects	10–20 mg oral (as capsule formulation)	Oral	10–30 days

Important caveats: Doses used in cell culture experiments cannot be directly extrapolated to whole-organism studies. Animal doses cannot be reliably scaled to humans using simple body weight ratios — allometric scaling, species-specific pharmacokinetics, and route-of-administration differences all affect dose translation. The oral capsule formulations referenced in Russian clinical studies contain Pinealon as part of a bioregulator preparation, and their formulation may differ from pure synthetic tripeptide. No internationally registered clinical trial has established a validated human dosing protocol for Pinealon as a standalone research compound.

Safety Profile

The safety data available for Pinealon is limited compared to peptides that have undergone formal regulatory review in Western markets. The following summarizes what has been reported in the published literature:

Preclinical Safety Data

• Acute toxicity — Published animal studies have reported no observed acute toxicity at the doses employed in research protocols. The Khavinson group has described Pinealon and related short peptide bioregulators as having wide safety margins in rodent models, with no lethal dose identified at multiples significantly exceeding the studied dose ranges.
• Subchronic administration — In studies involving repeated administration over periods of 10 to 30 days, no significant adverse effects on organ function, hematological parameters, or body weight have been reported in treated animals compared to controls.
• Genotoxicity and mutagenicity — The Khavinson group has reported that Pinealon and other short peptide bioregulators did not demonstrate genotoxic or mutagenic activity in standard screening assays, including the Ames test. However, independent replication of these findings by laboratories outside the original research group is limited.

Human Safety Data

Pinealon-containing bioregulator formulations have been used in clinical practice in Russia, where several short peptide bioregulators have received regulatory approval as dietary supplements or parapharmaceuticals. Reports from this clinical use have not documented significant adverse effects, though it should be noted that the post-marketing surveillance and adverse event reporting systems in this context may differ from those in FDA- or EMA-regulated environments.

No Phase I safety trial conducted under ICH-GCP (International Council for Harmonisation — Good Clinical Practice) guidelines has been published for Pinealon. The absence of formal pharmacokinetic data — including absorption, distribution, metabolism, and excretion (ADME) profiles in humans — represents a significant gap in the safety characterization of this peptide.

Theoretical Considerations

• Gene regulatory activity — Any compound proposed to interact with DNA and modulate gene expression warrants careful evaluation regarding potential off-target gene effects. While published studies have not reported evidence of aberrant gene activation or silencing, the selectivity and specificity of Pinealon’s gene regulatory actions have not been comprehensively mapped using modern genomic techniques such as whole-transcriptome sequencing.
• Interactions with endogenous melatonin regulation — If Pinealon genuinely modulates melatonin synthesis pathways, long-term administration could theoretically affect endogenous circadian regulation. The consequences of sustained exogenous modulation of melatonin synthesis have not been characterized in long-duration studies.

Researchers considering Pinealon in study designs should consult with their institutional review boards and adhere to all applicable regulatory guidelines. The current safety literature, while not raising specific red flags, is insufficient to establish a comprehensive safety profile by international regulatory standards.

Limitations of Current Research

A transparent assessment of Pinealon research requires acknowledgment of several significant limitations in the existing evidence base:

• Concentration of research in a single group — The majority of published Pinealon research originates from the Khavinson laboratory and collaborating institutions in Russia. While this body of work is substantial, the scientific standard of independent replication by unaffiliated research groups has been only partially met. Independent validation is essential for establishing the reliability and generalizability of reported findings.
• Limited Western peer-reviewed publications — While some Pinealon research has been published in internationally indexed journals, a significant portion of the literature exists in Russian-language publications that may not be accessible to the broader international research community. This limits critical evaluation and independent assessment of the reported findings.
• Mechanistic gaps — The gene regulatory peptide hypothesis, while supported by experimental data from the Khavinson group, has not been independently confirmed using contemporary structural biology techniques such as X-ray crystallography or cryo-EM to visualize peptide-DNA interactions at atomic resolution. The specificity of proposed DNA binding interactions has not been fully characterized.
• No registered clinical trials — As of early 2026, no clinical trial for Pinealon has been registered on ClinicalTrials.gov or equivalent international trial registries. The human data that exists comes from Russian clinical practice rather than controlled, randomized trials conducted under international GCP standards.
• Translation uncertainty — Even where preclinical results are encouraging, the translation from cell culture and rodent models to human physiology remains uncertain. This limitation applies broadly to peptide bioregulator research and is not unique to Pinealon.

Summary

Pinealon (Glu-Asp-Arg) represents a distinctive approach to neuropeptide research within the Khavinson bioregulator framework. As an ultra-short tripeptide proposed to regulate gene expression in pineal gland and central nervous system tissues, it occupies a unique position at the intersection of neuroendocrine research, circadian biology, and neuroprotection.

The published research on Pinealon — while predominantly preclinical and largely originating from a single research group — has documented several observations of scientific interest: promotion of melatonin synthesis in pinealocyte models, neuroprotective effects against oxidative stress and excitotoxicity in neuronal cultures, and potential modulation of circadian-related gene expression. Its ultra-short peptide structure, which facilitates blood-brain barrier penetration, addresses a fundamental challenge in CNS-targeted peptide research.

However, the evidence base for Pinealon remains in early stages by international research standards. The gene regulatory mechanism, while theoretically compelling, requires more extensive independent validation. No controlled clinical trials have been conducted under international regulatory standards, and formal pharmacokinetic and safety data in humans are lacking. These gaps represent both limitations of the current knowledge base and opportunities for future research.

For researchers investigating pineal gland function, circadian regulation, or neuroprotective mechanisms, Pinealon offers a well-defined molecular tool with a specific proposed target tissue and mechanism. Its relationship to other Khavinson bioregulators — including Cortagen (brain cortex), Crystagen (immune system), Vesugen (vascular system), and Cardigen (cardiac tissue) — provides context for multi-tissue bioregulation research programs. Its connections to sleep and neuroprotection research also intersect with the literature on DSIP and other neuroactive peptides.

As with all compounds in this research category, the progression from preclinical observations to established scientific consensus requires rigorous, independent, controlled studies — a standard that Pinealon research is still working toward.

Explore NorthPeptide’s catalog of research-grade Pinealon and related bioregulator peptides including Cortagen, Crystagen, Vesugen, and Cardigen.

---

Summary of Key Research References

Study	Year	Type	Focus	Reference
Ilina et al.	2020	In Vitro	EDR peptide mechanisms in Alzheimer’s disease gene expression regulation	PMC7795577
Khavinson et al.	2012	In Vivo	Pinealon protects rat offspring from prenatal hyperhomocysteinemia	PMC3342713
Khavinson et al.	2022	Review	Neuroepigenetic mechanisms of ultrashort peptides in Alzheimer’s disease	PMC9032300
Khavinson et al.	2021	In Vivo	Neuroprotective effects of tripeptides as epigenetic regulators in Alzheimer’s model	PMC8227791
Ilina et al.	2024	In Vitro	Short peptides protect induced neurons from age-related changes	PMC11546785
Khavinson et al.	2021	Review	Peptide regulation of gene expression: a systematic review	PMC8619776
Khavinson et al.	2005	In Vivo	Pineal peptides restore age-related hormonal disturbances	PubMed 15664732
Khavinson et al.	2025	Review	Overview of Epitalon: highly bioactive pineal tetrapeptide properties	PMC11943447